This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of fingolimod
MSMED_FINGOLIMOD
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
349 |
4. Check minimum number of events
Min. number of events
3
|
349 |
5. Include endpointsNone |
349 |
6. Filter based on genotype QC (FinnGen only) |
349 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of fingolimod
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 349 | 285 | 64 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.03 |
| Median age at first event (years) | 38.21 | 37.82 | 39.94 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 304
- Matched controls
- 3039
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
109
Kela drug reimbursment
Multiple sclerosis
11336.6
323.0
300
18
L04AA27
ATC
fingolimod; oral
+∞
323.0
304
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
323.0
304
25
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
323.0
267
*
164
Kela drug reimbursment
Fingolimod
+∞
323.0
304
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
1012.2
306.9
254
15
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
873.4
302.7
253
17
L03AB07
ATC
interferon beta-1a; parenteral
562.6
193.3
173
7
L03AX13
ATC
glatiramer acetate; parenteral
1162.9
188.5
165
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
52.3
169.6
217
138
N86
ICPC
Multiple sclerosis
499.3
130.3
121
*
H46
ICD-10 Finland
Optic neuritis
148.0
127.6
129
15
L03AB08
ATC
interferon beta-1b; parenteral
710.8
105.5
98
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
17.1
97.2
181
240
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
99.1
85.1
91
13
N04BB01
ATC
amantadine; oral
96.3
73.4
79
11
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
56.6
68.4
80
19
M03BX01
ATC
baclofen; systemic
61.3
61.6
71
15
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
68.2
61.0
69
13
ZX120
NOMESCO Finland
Intravenous
15.7
51.8
89
78
2AB04
NOMESCO Finland
NA
290.8
49.6
49
*
L04AA31
ATC
teriflunomide; oral
113.6
45.3
48
5
XCW99
NOMESCO Finland
Other investigative procedure of eye
12.5
45.1
86
93
XKD00
NOMESCO Finland
Uroflowmetry
16.5
44.6
74
58
TAB00
NOMESCO Finland
Lumbar puncture
12.8
43.2
81
84
XCK00
NOMESCO Finland
Perimetry
17.5
42.8
69
50
G04BD12
ATC
mirabegron; oral
15.6
42.5
72
59
L04AX07
ATC
dimethyl fumarate; oral
99.9
40.0
43
5
H02AB04
ATC
methylprednisolone; systemic
7.3
39.2
108
214
N07XX09
ATC
[U] dimethyl fumarate; oral
209.8
36.6
37
*
4AA23
NOMESCO Finland
NA
209.8
36.6
37
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
26.9
34.8
48
21
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
8.8
33.8
78
115
N06BA07
ATC
modafinil; oral
101.8
33.5
36
*
G04BD09
ATC
trospium; oral
34.5
32.6
42
14
XA800
NOMESCO Finland
Neuropsychological investigation
13.3
32.2
58
53
XKC03
NOMESCO Finland
Water cystometry
21.9
28.8
42
22
G04BD08
ATC
solifenacin; oral
15.7
28.4
47
35
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.9
27.6
67
105
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
12.8
27.6
50
46
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
102.5
26.1
28
*
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
283.4
26.1
26
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
8.5
25.7
59
84
UKC02
NOMESCO Finland
Cystoscopy
7.6
25.5
63
101
N03AX12
ATC
gabapentin; oral
5.4
25.1
85
205
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
271.4
25.1
25
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.5
24.5
56
79
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
18.1
23.9
37
23
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
10.3
23.3
47
53
N05CF01
ATC
zopiclone; oral
3.6
21.2
121
470
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.1
20.3
47
67
N03AX16
ATC
pregabalin; oral
3.8
20.2
101
349
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
12.6
19.6
35
31
R20.2
ICD-10 Finland
Paraesthesia of skin
5.8
19.3
58
119
H53.2
ICD-10 Finland
Diplopia
13.1
18.3
32
27
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.7
17.5
46
79
TKC22
NOMESCO Finland
Catheterisation instruction
27.5
17.2
23
9
R35
ICD-10 Finland
Polyuria
8.4
17.0
38
51
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
+∞
16.8
16
*
A02BC02
ATC
pantoprazole; systemic
2.9
16.8
211
1336
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
24.7
16.7
23
10
R1250
NOMESCO Finland
Evaluation of functional capability
15.5
16.7
27
19
C10AC01
ATC
colestyramine; oral
12.2
16.1
29
26
G04BD07
ATC
tolterodine; oral
12.7
15.9
28
24
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
15.8
15
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
40.4
15.6
19
5
XCK10
NOMESCO Finland
Photography of fundus of eye
6.2
15.4
42
76
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.1
14.5
98
408
N29
ICPC
Neurological sympt/complt other
18.7
14.0
21
12
N03AE01
ATC
clonazepam; systemic
6.4
13.7
36
62
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
13.6
113
536
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
11.2
13.5
25
24
L28
ICPC
Limited function/disability (L)
4.7
13.5
47
113
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
42.1
13.3
16
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
4.0
13.3
56
162
SPAT1229
SPAT
Assessment of need for aid
7.5
13.3
31
45
RF120
NOMESCO Finland
NA
20.2
13.1
19
10
L04AA40
ATC
cladribine; oral
+∞
12.6
12
*
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
12.6
12
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
39.3
12.3
15
*
XKD03
NOMESCO Finland
Urethral pressure profilometry
13.2
12.3
21
17
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
10.7
12.2
23
23
RF420
NOMESCO Finland
NA
19.0
12.2
18
10
RF410
NOMESCO Finland
NA
22.4
12.1
17
8
G04BD04
ATC
oxybutynin; oral, transdermal
9.2
11.8
24
28
L01BB04
ATC
cladribine; systemic
+∞
11.5
11
*
XCD10
NOMESCO Finland
Electrophysiological examination of eye
12.5
11.5
20
17
J05AB01
ATC
aciclovir; systemic
2.7
11.1
91
420
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.7
11.0
25
35
L03AB13
ATC
peginterferon beta-1a; parenteral
45.1
11.0
13
*
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
29.2
10.8
14
5
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
22.4
10.8
15
7
J01EA01
ATC
trimethoprim; systemic
2.5
10.6
103
521
R4110
NOMESCO Finland
Physiotherapy
2.6
10.3
86
398
R4120
NOMESCO Finland
Occupational therapy
4.9
10.1
33
74
N30.0
ICD-10 Finland
Acute cystitis
3.2
10.0
56
201
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
20.9
9.9
14
7
G04CA01
ATC
alfuzosin; oral
8.3
9.8
21
27
N04BD01
ATC
selegiline; oral
56.9
9.7
11
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
6.4
9.4
24
40
J05AB11
ATC
valaciclovir; oral
3.1
9.4
56
209
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.7
9.4
31
71
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.5
9.3
27
53
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
9.2
32
77
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.9
8.7
28
62
R4150
NOMESCO Finland
Neuropsychological rehabilitation
12.1
8.7
15
13
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
28.4
8.5
11
*
G04BD11
ATC
fesoterodine; oral
11.2
8.4
15
14
A06AD11
ATC
lactulose; oral
3.9
8.1
33
93
J01AA02
ATC
doxycycline; systemic
2.2
7.9
239
1906
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
46.2
7.8
9
*
G50.0
ICD-10 Finland
Trigeminal neuralgia
12.3
7.6
13
11
SPAT1325
SPAT
Vaccination
2.2
7.6
87
467
J01CA08
ATC
pivmecillinam; oral
2.0
7.5
155
1052
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
82.0
7.4
8
*
U13
ICPC
Bladder symptom/complaint other
8.7
7.4
15
18
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
7.3
7
*
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
30.8
7.2
9
*
G51.0
ICD-10 Finland
Bell palsy
6.6
7.0
17
27
H02AB06
ATC
prednisolone; systemic
1.9
7.0
143
960
RS340
NOMESCO Finland
NA
41.0
6.8
8
*
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
14.7
6.4
10
7
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
27.3
6.3
8
*
SPAT1231
SPAT
Assessment of adjustments needed in living environment
27.3
6.3
8
*
H53.1
ICD-10 Finland
Subjective visual disturbances
3.5
6.2
27
82
Z50.1
ICD-10 Finland
Other physical therapy
4.3
6.1
21
51
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
12.9
6.1
10
8
N06AX16
ATC
venlafaxine; oral
2.2
6.1
66
342
M03BX02
ATC
tizanidine; oral
1.9
6.1
210
1653
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
135
59
36.69
196.39
1.2
1.1
—
—
—
0
0
90
8
150.92
87.79
2.9
2.6
—
—
—
0
0
54
19
33.44
81.96
2.2
2.7
15.4
9.4
%
1.83
26
11
52
17
35.77
80.70
2.1
2.9
—
—
—
0
0
337
1619
32.45
70.31
20.4
8.3
3.4
3.9
e9/l
11.04
332
1430
220
739
6.35
65.28
7.3
2.6
—
—
—
0
0
186
555
6.03
62.65
5.7
2.3
0.1
0.2
e6/l
1.53
161
398
62
59
12.56
58.49
5.9
3.7
3.4
4.0
e9/l
1.65
62
59
62
59
12.56
58.49
6.0
3.9
67.5
56.4
%
9.51
62
59
52
41
14.73
54.95
1.2
1.1
—
—
—
0
0
272
1222
6.56
54.30
6.8
5.2
9.7
9.5
umol/l
0.19
264
1155
31
17
19.92
39.09
1.3
1.1
1657.8
1558.2
miu/ml
0.15
31
17
110
312
4.69
36.61
4.8
2.1
0.9
0.8
e6/l
0.11
63
160
39
7
62.45
34.01
1.2
1.0
—
—
—
0
0
294
1762
5.24
32.44
10.8
3.5
45.3
966.3
e6/l
—
6
14
101
303
4.28
30.73
5.0
2.1
6.3
4.1
e6/l
0.39
53
151
221
1136
3.58
29.42
2.5
2.3
97.9
72.7
nmol/l
21.66
212
1083
244
1386
3.53
26.59
7.8
2.8
0.0
0.0
estimate
0.00
74
257
241
1365
3.47
26.25
9.7
3.9
0.0
0.0
estimate
0.50
73
266
241
1371
3.45
25.93
7.9
2.8
0.0
0.0
estimate
0.00
74
259
24
21
12.20
23.36
1.0
1.0
—
—
—
0
0
56
130
4.94
23.21
1.5
1.4
—
—
—
0
0
23
25
9.78
19.30
1.1
1.2
54.8
31.3
mg/l
1.41
16
20
25
31
8.61
19.00
4.5
1.9
639.4
846.8
e6/l
0.64
13
13
21
5
44.58
17.48
1.1
1.2
—
—
—
0
0
82
307
3.18
17.04
2.7
2.1
72.7
2764.5
u/l
2.84
20
128
20
5
42.31
16.51
1.6
4.0
—
—
—
0
0
180
1079
2.38
14.13
9.0
2.7
—
—
—
0
0
21
33
6.71
12.97
1.0
1.1
—
—
—
0
0
30
69
4.66
12.42
1.4
1.7
0.9
129.8
e6/l
0.96
24
56
30
69
4.66
12.42
1.2
1.7
12.6
4.6
e6/l
1.49
23
53
127
688
2.33
12.20
11.0
3.0
0.0
0.0
estimate
1.08
72
264
20
34
6.18
11.46
1.0
1.1
—
—
—
0
0
13
13
10.35
11.40
6.6
1.5
—
—
—
0
0
19
32
6.22
10.97
1.0
1.2
—
—
—
0
0
58
240
2.70
9.75
3.2
1.7
—
—
—
0
0
225
2723
0.51
7.80
2.8
3.0
1.2
1.2
mmol/l
0.03
214
2607
238
2826
0.50
7.67
2.9
3.3
1.5
1.5
mmol/l
0.75
225
2714
243
2849
0.52
7.01
3.0
3.4
3.1
2.9
mmol/l
1.17
226
2727
241
2832
0.52
6.98
2.9
3.3
4.9
4.8
mmol/l
1.35
229
2724
271
2224
1.98
6.56
5.9
2.8
55.0
35.1
u/l
5.29
266
2151
243
1955
1.80
5.89
6.1
6.3
74.4
71.8
u/l
0.53
234
1840
328
2951
2.85
5.54
13.4
9.3
14.7
18.0
mg/l
1.16
246
2221
11
25
4.51
4.59
1.2
1.6
—
—
—
0
0
310
2767
2.08
4.56
9.7
8.5
3.9
3.9
mmol/l
0.20
301
2679
308
2756
2.00
4.29
9.6
8.5
139.8
139.5
mmol/l
1.86
300
2681
38
189
2.13
4.22
1.2
1.3
174.4
278.8
miu/ml
1.21
14
96
175
1369
1.56
4.03
3.2
3.6
6.0
6.2
mmol/l
1.54
166
1224
233
2658
0.63
3.87
2.8
3.2
5.5
5.6
mmol/l
0.45
215
2510
51
295
1.85
3.72
1.4
1.8
—
—
—
0
0
121
885
1.56
3.68
4.5
4.3
38.6
37.6
g/l
1.67
108
830
296
2674
1.70
3.20
11.9
7.3
100.5
95.6
ml/min/173m2
5.23
270
2144
6
9
6.76
2.88
1.2
2.0
—
—
—
0
0
26
463
0.53
2.60
1.2
1.5
—
—
—
0
0
15
312
0.46
2.37
1.2
1.5
—
—
—
0
0
6
13
4.68
2.28
1.2
1.2
—
—
—
0
0
32
188
1.77
2.26
1.3
1.7
—
—
—
0
0
12
265
0.43
2.23
1.1
1.4
—
—
—
0
0
12
265
0.43
2.23
1.1
1.4
—
—
—
0
0
26
440
0.56
2.19
1.2
1.6
—
—
—
0
0
14
288
0.46
2.16
1.1
1.5
—
—
—
0
0
32
191
1.74
2.15
1.3
1.7
—
—
—
0
0
215
2400
0.73
2.13
3.5
3.9
35.8
37.4
mmol/mol
2.65
200
2307
13
266
0.47
1.99
1.1
1.4
—
—
—
0
0
13
266
0.47
1.99
1.1
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
17
3.57
1.84
1.0
1.2
—
—
—
0
0
39
556
0.66
1.63
1.2
1.2
2.4
6.1
u/ml
0.89
13
238
5
15
3.37
1.53
1.0
1.3
—
—
—
0
0
9
180
0.49
1.44
1.6
1.7
—
—
—
0
0
119
1005
1.28
1.36
5.1
5.5
1.2
1.2
mmol/l
0.10
96
856
19
113
1.72
1.34
3.5
2.1
12.4
5.5
iu/l
—
9
47
49
644
0.72
1.31
1.3
1.6
1.2
1.5
mmol/l
3.09
39
581
282
2959
0.76
1.22
20.7
10.1
39.8
40.4
%
0.57
226
2567
5
20
2.52
1.15
1.0
1.4
—
—
—
0
0
0
36
0.00
1.14
0.0
1.6
—
—
—
0
0
113
1305
0.80
1.14
3.8
3.8
—
—
—
0
0
63
779
0.77
1.12
1.9
1.9
—
—
—
0
0
15
90
1.70
1.05
1.9
2.0
—
—
—
0
0
5
106
0.46
1.03
7.4
2.7
1.3
0.6
mmol/l
—
5
67
72
866
0.79
1.02
1.9
2.1
—
—
—
0
0
5
109
0.45
1.02
7.4
2.7
4.9
5.0
kpa
—
5
100
9
158
0.56
1.01
1.3
1.5
—
—
—
0
0
7
35
2.02
1.00
1.0
1.4
—
—
—
0
0
14
84
1.69
0.99
1.2
1.7
—
—
—
0
0
5
23
2.19
0.98
1.0
1.4
—
—
—
0
0
5
23
2.19
0.98
1.0
1.5
—
—
—
0
0
48
603
0.76
0.96
1.8
2.0
2.0
2.8
mg/l
3.62
39
531
47
372
1.30
0.89
2.4
2.4
511.1
232.2
ng/l
0.24
11
174
20
136
1.50
0.88
1.5
1.6
—
—
—
0
0
101
877
1.21
0.87
4.9
4.7
1.2
1.2
mmol/l
0.81
94
816
11
178
0.61
0.85
1.1
2.0
—
—
—
0
0
6
114
0.52
0.84
2.0
1.4
0.5
0.4
nmol/l
—
6
93
147
1618
0.84
0.84
2.7
2.9
79.5
68.9
ug/l
0.32
137
1546
261
2733
0.82
0.83
3.6
4.0
—
—
—
0
0
102
891
1.20
0.82
1.7
1.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.3
—
—
—
0
0
0
27
0.00
0.77
0.0
1.0
—
1.1
—
0
10
5
24
2.10
0.75
1.0
1.4
—
—
—
0
0
13
84
1.57
0.73
1.8
1.8
—
—
—
0
0
31
396
0.76
0.72
1.7
1.8
—
—
—
0
0
26
340
0.75
0.71
1.7
2.2
2.4
2.4
mmol/l
0.26
19
296
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
29
371
0.76
0.68
1.6
1.3
29.9
24.3
iu/l
0.44
29
320
8
49
1.65
0.62
1.4
1.6
—
—
—
0
0
8
50
1.61
0.61
1.4
3.6
—
457.3
—
0
6
5
30
1.68
0.61
1.0
1.4
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
95.7
—
0
16
0
22
0.00
0.59
0.0
1.9
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
16
217
0.72
0.57
1.3
1.5
—
—
—
0
0
6
40
1.51
0.52
1.0
1.1
—
—
—
0
0
7
110
0.63
0.49
1.4
1.4
34.8
54.1
pmol/l
—
7
105
44
513
0.84
0.48
1.8
1.9
—
—
—
0
0
24
194
1.25
0.43
1.7
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
37.4
—
0
10
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
2.0
—
—
—
0
0
0
17
0.00
0.40
0.0
2.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.6
—
—
—
0
0
80
727
1.13
0.40
2.7
2.3
10.0
21.0
ng/l
1.53
28
264
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
35
300
1.19
0.38
1.5
1.6
1089.3
1145.6
nmol/l
0.16
27
245
5
80
0.62
0.35
1.0
1.2
—
—
—
0
0
9
125
0.71
0.35
1.6
1.5
—
—
—
0
0
7
55
1.28
0.30
1.0
1.3
—
1.2
—
0
7
49
441
1.13
0.30
1.5
1.5
485.1
37772811.5
pmol/l
0.80
42
413
51
563
0.89
0.29
1.2
1.3
9.3
22.5
iu/ml
2.88
11
175
11
85
1.30
0.28
1.0
1.2
—
15.9
—
0
19
25
215
1.18
0.27
5.7
4.7
—
—
—
0
0
22
257
0.85
0.27
3.8
2.3
27.6
24.6
%
0.39
17
218
280
2745
1.10
0.27
6.5
4.8
1.6
2.1
mu/l
0.61
264
2644
5
71
0.70
0.26
1.0
1.2
—
—
—
0
0
5
71
0.70
0.26
1.0
1.9
—
—
—
0
0
91
968
0.92
0.26
1.5
1.6
—
—
—
0
0
18
213
0.84
0.26
1.2
1.4
—
—
—
0
0
82
767
1.09
0.25
2.2
3.1
2.3
2.3
mmol/l
0.39
75
708
17
202
0.83
0.25
1.6
2.0
15.1
36.0
u/ml
1.16
17
192
70
650
1.10
0.25
1.6
1.7
0.5
0.7
mg/l
0.41
44
475
23
198
1.17
0.25
1.0
1.1
—
—
—
0
0
5
41
1.22
0.22
1.2
1.2
—
—
—
0
0
5
41
1.22
0.22
1.2
1.2
—
—
—
0
0
208
2025
1.07
0.22
2.7
3.4
7.3
8.2
mm/h
0.80
197
1919
5
42
1.19
0.21
1.2
1.6
—
13.5
—
0
5
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.25
0.20
1.0
1.6
—
—
—
0
0
19
166
1.15
0.18
2.3
2.1
12.7
13.5
nmol/l
0.17
19
156
5
66
0.75
0.17
1.8
1.3
450.8
197.7
u/ml
—
5
39
5
67
0.74
0.17
1.0
1.3
—
4.7
—
0
24
22
197
1.12
0.15
3.1
2.5
—
—
—
0
0
12
140
0.85
0.15
17.4
7.5
7.0
7.1
mmol/l
0.01
12
135
30
327
0.91
0.15
1.6
1.3
85.9
149.5
iu/ml
1.18
14
148
87
834
1.06
0.15
1.5
1.7
100.8
96.0
pmol/l
0.31
43
477
10
117
0.85
0.13
1.1
1.4
—
—
—
0
0
9
109
0.82
0.13
1.2
2.2
—
—
—
0
0
13
114
1.15
0.12
1.2
1.3
—
—
—
0
0
14
157
0.89
0.11
1.4
1.2
10.8
10.6
u/l
0.02
14
129
10
115
0.87
0.11
1.2
1.5
1.1
1.2
g/l
—
10
109
58
605
0.95
0.10
1.8
1.8
—
—
—
0
0
5
46
1.09
0.09
1.0
1.0
—
—
—
0
0
6
72
0.83
0.07
1.0
1.1
—
—
—
0
0
6
73
0.82
0.07
1.7
1.2
—
—
—
0
0
9
86
1.05
0.07
1.1
1.2
—
—
—
0
0
9
87
1.04
0.07
1.1
1.2
—
—
—
0
0
8
90
0.89
0.07
3.4
7.8
2.2
1.5
%
—
8
90
9
104
0.86
0.06
1.3
1.2
1.4
2.7
ug/l
—
9
93
237
2386
0.98
0.04
5.9
4.3
14.9
14.2
pmol/l
4.75
221
2279
19
200
0.95
0.04
1.5
1.4
—
—
—
0
0
15
159
0.94
0.03
3.1
6.8
0.3
0.6
mmol/l
—
8
120
16
169
0.94
0.03
2.3
1.9
85.8
87.5
ml/min/173m2
—
9
69
81
798
1.02
0.03
1.3
1.3
0.4
2.2
u/ml
1.96
22
229
10
98
1.02
0.00
1.8
1.6
96.5
95.0
%
—
10
92
13
131
0.99
0.00
1.8
1.8
—
—
—
0
0
15
155
0.97
0.00
12.7
9.8
1.0
1.1
inr
—
6
32
11
106
1.04
0.00
1.1
1.1
—
—
—
0
0
17
174
0.98
0.00
1.7
2.6
0.2
0.2
g/l
0.37
17
167
0
6
0.00
0.00
0.0
1.0
—
479.7
—
0
6
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
2.6
—
0
6
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.0
—
0
5
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
0.7
—
0
9
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
0.0
—
0
8
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
0.00
1.0
1.6
—
—
—
0
0
5
54
0.92
0.00
1.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
7.1
—
0
9
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_FINGOLIMOD – Use of fingolimod
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).